Showing 5391-5400 of 7030 results for "".
- PsO Pipeline Update: First Cohort of Patients Dosed with LNK01004 in Phase Ib Studyhttps://practicaldermatology.com/news/pso-pipeline-update-first-cohort-of-patients-dosed-with-lnk01004-in-phase-ib-study/2461742/The first cohort of psoriatic patients have been dosed in a Phase Ib clinical trial of Lynk Pharmaceuticals Co., Ltd.’s LNK01004. The trial was designed to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of LNK01004 ointment in Chinese p
- FDA Nod for Cyltezo Autoinjector Penhttps://practicaldermatology.com/news/fda-nod-for-cyltezo-autoinjector-pen/2461738/The U.S. Food and Drug Administration (FDA) has approved Boehringer Ingelheim’s Cyltezo Pen, a new autoinjector option for Cyltezo (adalimumab-adbm). Cyltezo is an FDA-approved interchangeable biosimilar to Humira (adalimumab). Initially approved as a pre
- First Patient Dosed in TrialSpark's Phase 2 Trial of ASN008-201 in ADhttps://practicaldermatology.com/news/first-patient-dosed-in-trailsparks-phase-2-trial-of-asn008-201-in-ad/2461736/The first patient has been dosed in TrialSpark’s Phase 2 clinical trial for ASN008-201, a topical sodium channel blocker in development for pruritus associated with atopic dermatitis (AD). This clinical trial is a randomized, double-blind, vehicle-controlled, Phase 2 tr
- AAD Survey: Too Few Folks Use Sun Protection During Outdoor Activitieshttps://practicaldermatology.com/news/aad-survey-too-few-folks-use-sun-protection-during-outdoor-activities/2461735/Although 90% of Americans report protecting themselves from the sun when going to beaches or pools, far fewer plan for it before other outdoor activities, according to a recent American Academy of Dermatology (AAD) survey of more than 1,000 U.S. adults. "The head, neck, arms, and l
- FDA Approves First Topical Gene Therapy for Treatment of Wounds in Patients with DEBhttps://practicaldermatology.com/news/fda-approves-first-topical-gene-therapy-for-treatment-of-wounds-in-patients-with-deb/2461732/The U.S. Food and Drug Administration approved Vyjuvek, a herpes-simplex virus type 1 (HSV-1) vector-based gene therapy, for the treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) g
- ASA, Nicklaus Companies, and ahead Partner to Educate Golfers on Sun Safetyhttps://practicaldermatology.com/news/asa-nicklaus-companies-and-ahead-partner-to-educate-golfers-on-sun-safety/2461730/Nicklaus Companies and ahead, a provider of premium golf and leisure headwear, are joining forces with American Skin Association (ASA) to raise awareness about melanoma and educate golfers on the importance of sun safety. Both companies will use their social platforms to provide aw
- AI In Action: Machine Learning Algorithms May Aid Diagnosis and Treatment of ADhttps://practicaldermatology.com/news/ai-in-action-machine-learning-algorithms-may-aid-diagnosis-and-treatment-of-ad/2461726/Researchers have developed six relatively stable and reliable diagnosis and efficacy evaluation prediction models for atopic dermatitis (AD) based on a machine learning algorithm. Songjiang Wu, a PhD candidate in dermatology from Third Xiangya Hospital at the Central South University in
- Study: Spironolactone May Be an Alternative to Antibiotics for Women With Persistent Acnehttps://practicaldermatology.com/news/study-spironolactone-may-be-an-alternative-to-antibiotics-for-women-with-persistent-acne/2461725/Spironolactone could be a cheap and readily available alternative to antibiotics for women with persistent acne, according to research out of the University of Southampton. The results of the trial appear in the Bri
- First Subject Dosed in Phase 1 Clinical Study of NM26 for ADhttps://practicaldermatology.com/news/first-subject-dosed-in-phase-1-clinical-study-of-nm26-for-ad/2461718/The first subject has been dosed in the Phase 1 clinical study of Numab Therapeutics’ NM26-2198, a first-in-class bi-specific antibody for the treatment of moderate-to-severe atopic dermatitis (AD). This marks the beginning of a combined single ascending dose (SAD) and multip
- Oral IL-23 Receptor Antagonist Makes Waves in Tokyohttps://practicaldermatology.com/news/oral-il-23-receptor-antagonist-makes-waves-in-tokyo/2461716/Protagonist Therapeutics and Janssen Biotech, Inc.'s oral IL-23 receptor antagonist, JNJ-2113, performed well in Phase 1 and Pre-clinical Studies. JNJ-2113 is a macrocyclic peptide that binds to the IL-23 receptor with single digit picomolar affinity and demonstr